A controlled multicenter trial of 2,3-dihydro-1-H-pyridino (2,3-b)(1,4)-thiazine-2-one in rheumatoid arthritis.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012737:Sex Factors; D013223:Statistics as Topic; D013843:Thiazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D011725:Pyridines; D013843:Thiazines; D001241:Aspirin